← All Co-diagnostics, INC filings

Co-diagnostics, INC 8-K filings

NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics, Inc. Holds 2024 Annual Meeting, Elects Director and Approves Executive Compensation
Co-Diagnostics, Inc. held its 2024 annual meeting, electing a director, approving executive compensation, and ratifying the appointment of its accounting firm.
NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics Reports Improved Second Quarter 2024 Financial Results Amidst FDA Application Progress
Co-Diagnostics saw a significant increase in revenue and reduced operating losses in Q2 2024, driven by grant milestones and lower expenses, while also submitting a key FDA application.
NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics Submits FDA Application for Co-Dx PCR Pro Platform
Co-Diagnostics has submitted its first FDA 510(k) application for its Co-Dx PCR Pro platform and COVID-19 test for over-the-counter use.
NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics Reports First Quarter 2024 Financial Results with Increased Operating Loss
Co-Diagnostics reported a decrease in revenue and an increased net loss for the first quarter of 2024, alongside strategic expansions and leadership changes.
NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics Appoints Richard Abbott as President
Co-Diagnostics, Inc. has appointed Richard Abbott as President, effective March 15, 2024.
NASDAQ
CODX
Co-diagnostics, INC
8-K: Co-Diagnostics Reports Full Year 2023 Results Amidst COVID-19 Test Demand Decline
Co-Diagnostics reported a significant decrease in revenue for 2023 due to reduced demand for COVID-19 tests, alongside increased investment in new platform development.